The World Market for Gynaecology

2007-2017

Publication Date September 2007
ISBN n/a
Pages 350
Tables 99
Figures 20

Print £3225 $5055

 Add to Basket

PDF £3200 $5020

Single user

 Add to Basket

PDF £14400 $22575

Companywide user

 Add to Basket
Provides a unique assessment of current developments and prospective factors that will shape the global female health market over the next decade.

Spectra's World Market for Gynaecology, 2007-2017 provides a unique assessment of current developments and prospective factors that will shape the global female health market over the next decade. This unrivalled, in-depth market research study commissioned by one of the top three multinational pharmaceutical companies presents a detailed and comprehensive analysis of prescription products used in the diverse areas of infertility, contraception, gynaecological disorders, and menopause.

The market for gynaecology is predicated on hormonal drugs that have recently been subject to controversy based on reports of associated increased risks of cardiovascular disease and cancer. The global market has suffered as a consequence due to cautious prescribing approaches for hormone replacement therapies.

The pipeline however is vast with over 75 hormonal products in clinical development that will offer purer analogues, low-dose formulations, new delivery modes and formats, novel mechanisms of action, and which also confer sophisticated clinical effects over traditional products.

The market for gynaecology is showing signs of a significant upward growth trend over the forecast period to 2017 and the next decade will be exciting, but companies will need to differentiate their products and consider the market forces that may affect product revenue and portfolios.

The World Market for Gynaceology aims to provide an expert analysis of the prescription drug market for female health over the next decade based on current industrial insights, market factors and forces, and trend information. Study objectives include critical assessments of existing products, reviews of products in clinical development, therapy forecasting of product/portfolios to 2017, and market sector analytics by therapeutic category and discrete disorder.

Report Highlights And Key Findings
  • Commissioned by a market leader in Women's and Sexual Health, this report uniquely provides a comprehensive analysis of current and pipeline gynaecology products, which is not available elsewhere in the market literature;
  • Provides a concise overview of the conditions and diseases related to gynaecology including aetiology, epidemiology, and management;
  • Complete description of existing products to include reviews of product characteristics, side effects, and sales performance;
  • Extensive information on new gynaecological drugs in the pipeline, including product characteristics, technologies, research status, and the results of clinical trials;
  • Market analysis of the US and international markets for gynaecological prescription products with therapy area and sales forecasts to 2017;
  • Analysis of market dynamics for infertility, contraception, menstrual and gynaecological disorders, and menopause;
  • Product-focused appraisals and discussions for market potential and growth;
  • Benchmark analytics for current research themes and future therapy areas;
  • Evaluation of the key drivers and predictors of growth and innovation in gynaecology;
  • In-depth assessment of the commercial and drug development opportunities in the field.
  • Reports on the status of existing and pipeline gynaecology prescription products to 2017;
  • Highlights the drug development strategies that are being employed by companies to sustain leadership;
  • Provides a comprehensive description of gynaecological and obstetric drugs currently on the market;
  • Describes the pipelines and biological targets being pursued by a host of companies, both small and large;
  • Assists in analysing discovery programmes of competitors and aids decision-making for in-house research and development;
  • Provides critical information on how companies are reformulating hormonal drugs to solve market, clinical, and regulatory barriers;
  • Provides market trend data of best- and least-performing gynaecology products;
  • Identifies niche markets where there is an unmet need for gynaecological and obstetric therapeutics;
  • Provides forecasts of products, therapy areas, and drug classes to 2017;
  • Shows estimation of the global market for gynaecology to include both hormonal and nonhormonal products.
What Can I Learn From This Report?
  • The current armamentarium of gynaecology drugs including their advantages and disadvantages;
  • New hormonal and nonhormonal drugs in the pipeline and their mechanisms and product characteristics;
  • What gynaecological conditions represent the most important market sectors over the next decade;
  • Trend information for use of gynaecological products during the next 10 years;
  • Which gynaecological and obstetric drugs are currently competing with each other for the same indications;
  • How companies are expanding indications and reformulating their best-selling products;
  • Which products are destined for significant growth and market success;
  • Therapy areas forecasts and individual product sales estimates to 2017;
  • What niches of the gynaecology market are likely to provide high-growth sector opportunities;
  • Which classes of drugs are on course for major drug development;
  • Why some new formulations are likely to be attractive to patients and physicians;
  • How novel therapeutics might compete with traditional products in the global market.
  • Contents List
  • List of Tables
  • List of Figures
  • List of Abbreviations
  • Executive Summary
  • Objectives of the Report
  • Chapter 1. Reproduction: Infertility Andobstetric Conditions
    • 1.1 Infertility: Background and Epidemiology
      • 1.1.1 Assisted Conception
    • 1.2 Pharmacotherapies for Infertility
      • 1.2.1 Mechanism of Action of Infertility Pharmacotherapeutics
    • 1.3 Product and Market Review for Infertility Pharmacotherapeutics
      • 1.3.1 Company
        • 1.3.1.1 Key Product and Portfolio Review
        • 1.3.1.2 Sales Estimates and Product Market Outlook
      • 1.3.2 Company
        • 1.3.2.1 Key Product and Portfolio Review
        • 1.3.2.2 Pipeline Focus
        • 1.3.2.3 Sales Estimates and Product Market Outlook
      • 1.3.3 Company
        • 1.3.3.1 Key Product and Portfolio Review
        • 1.3.3.2 Pipeline Focus
        • 1.3.3.3 Sales Estimates and Product Market Outlook
      • 1.3.4 Company
        • 1.3.4.1 Key Product and Portfolio Review
        • 1.3.4.2 Pipeline Focus
        • 1.3.4.3 Sales Estimates and Product Market Outlook
    • 1.4 Obstetric Conditions
      • 1.4.1 Preeclampsia - Background
        • 1.4.1.1 Epidemiology
        • 1.4.1.2 Pharmacotherapy for Preeclampsia
        • 1.4.1.3 Product and Market Overview for Preeclampsia Pharmacotherapy
      • 1.4.2 Preterm Labour
        • 1.4.2.1 Epidemiology
        • 1.4.2.2 Prevention and Treatment
        • 1.4.2.3 Pharmacotherapy for Preterm Labour
        • 1.4.2.4 Product and Market Overview for Preterm Labour Pharmacotherapy
      • 1.4.3 Polycystic Ovary Syndrome
        • 1.4.3.1 Aetiology
        • 1.4.3.2 Epidemiological Data
        • 1.4.3.3 Economic Burden
        • 1.4.3.4 Current Treatments - The Evidence
        • 1.4.3.5 Product and Market Overview for Polycystic Ovary Syndrome
  • Chapter 2. Contraception
    • 2.1 Hormonal Contraception: Epidemiological Data
    • 2.2 Contraception: Inducing Infertility via Ovulation Suppression
    • 2.3 Contraceptive Formulations
      • 2.3.1 Combined Oestrogen-Progestogen Contraceptives
      • 2.3.2 Progestogen-Only Contraceptives
    • 2.4 Product Market for Hormonal Contraceptives
      • 2.4.1 Company
        • 2.4.1.1 Key Product and Portfolio Review
        • 2.4.1.2 Sales Estimates and Product Market Outlook
      • 2.4.2 Company
        • 2.4.2.1 Key Product and Portfolio Review
        • 2.4.2.2 Pipeline Focus
        • Male Contraception
        • 2.4.2.3 Sales Estimates and Product Market Outlook
      • 2.4.3 Company
        • 2.4.3.1 Key Product and Portfolio Review
        • 2.4.3.2 Sales Estimates and Product Market Outlook
      • 2.4.4 Company
        • 2.4.4.1 Key Product and Portfolio Review
        • 2.4.4.2 Pipeline Focus
      • 2.4.4 3 Sales Estimates and Product Market Outlook
      • 2.4.5 Company
        • 2.4.5.1 Key Product and Portfolio Review
        • 2.4.5.2 Pipeline Focus
        • 2.4.5.3 Sales Estimates and Product Market Outlook
      • 2.4.6 Company
        • 2.4.6.1 Key Product and Portfolio Review
        • 2.4.6.2 Pipeline Focus
        • 2.4.6.3 Sales Estimates and Product Market Outlook
    • 2.5 Intrauterine Devices
      • 2.5.1 Safety Concerns
      • 2.5.2 Epidemiological Data Related to Intrauterine Devices
      • 2.5.3 Types of Intrauterine Devices
        • 2.5.3.1 Copper-Bearing Intrauterine Devices
        • 2.5.3.2 New Generation Intrauterine Devices
      • 2.5.4 Product Market Overview for Intrauterine Devices
        • 2.5.4.1 Product Sales Estimates and Market Overview
  • Chapter 3. Menstrual And Gynaecological Disorders
    • 3.1 Pharmacotherapies for Menstrual and Gynaecological Disorders
      • 3.1.1 Mechanism of Action of Treatments for Menstrual and Gynaecological Disorders
    • 3.2 Menstrual Disorders: Prevalence, Pathophysiology and Management
      • 3.2.1 Pathophysiology of Menstruation
        • 3.2.1.1 Anovulation
        • Aetiology
        • Treatment
      • 3.2.2 Amenorrhoea
        • 3.2.2.1 Aetiology
        • 3.2.2.2 Epidemiology
        • 3.2.2.3 Pharmacotherapies for Amenorrhoea
        • 3.2.2.4 Product Market Overview for Amenorrhoea
      • 3.2.3 Dysmenorrhoea
        • 3.2.3.1 Epidemiology
        • 3.2.3.2 Primary Dysmenorrhoea
        • 3.2.3.3 Secondary Dysmenorrhoea
        • 3.2.3.4 Treatments for Dysmenorrhoea
        • 3.2.3.5 Product Market Overview for Dysmenorrhoea
        • 3.2.3.6 Future Treatments for Dysmenorrhoea
      • 3.2.4 Menorrhagia
        • 3.2.4.1 Epidemiology
        • 3.2.4.2 Treatments for Menorrhagia
        • 3.2.4.3 Product Market Overview for Menorrhagia
        • 3.2.4.4 Future Treatment Directions for Menorrhagia
      • 3.2.5 Oligomenorrhoea
        • 3.2.5.1 Aetiology
        • 3.2.5.2 Epidemiology
        • 3.2.5.3 Treatments for Oligomenorrhoea
      • 3.2.6 Suppression of Cycle
        • 3.2.6.1 Contraceptive Treatments for Suppression of Cycle
        • 3.2.6.2 Product Market Overview for Cycle Suppression
      • 3.2.6 Menstrual Syndromes
        • 3.2.6.1 Premenstrual Syndome
        • Aetiology
        • Epidemiology
        • Treatment Options for Premenstrual Syndrome
        • Drug Therapy for Premenstrual Syndrome
        • Product Market Overview for Premenstrual Syndrome
        • 3.2.6.2 Premenstrual Dysphoric Disorder
        • Aetiology
        • Epidemiology
        • Treatment for Premenstrual Dysphoric Disorder
        • Product Market Overview for Premenstrual Dysphoric Disorder
    • 3.3 Gynaecological Disorders: Prevalence, Pathophysiology and Management
      • 3.2.1 Pain-Related Gynaecological Disorders
        • 3.2.1.1 Vulvodynia
        • Epidemiology
        • Treatment for Vulvodynia
        • Product Market Overview for Vulvodynia
        • 3.2.1.2 Vestibulodynia
        • Epidemiology
        • Treatment for Vestibulodynia
        • Future Research Directions
      • 3.2.2 Uterine Disorders
        • 3.2.2.1 Endometriosis
        • Aetiology
        • Epidemiology
        • Severity and Symptoms
        • Treatments for Endometriosis
        • Hormonal Therapies for Endometriosis
        • Product Reviews
        • Product Market Overview for Endometriosis
        • 3.2.2.2 Uterine Fibroids
        • Epidemiology
        • Symptoms
        • Treatment Options for Uterine Fibroids
        • Pharmacotherapy for Uterine Fibroids
        • Product Market Overview for Uterine Fibroids
        • Future Research Directions for Uterine Fibroids
        • 3.2.2.3 Adenomyosis
        • Epidemiology
        • Treatment Options for Adenomyosis
        • Product Market Overview for Adenomyosis
      • 3.2.3 Vaginal Disorders
        • 3.2.3.1 Vaginal Atrophy
        • Symptoms of Vaginal Atrophy
        • Treatment for Vaginal Atrophy
        • 3.2.3.2 Vaginal Dryness
        • Epidemiology
        • Symptoms of Vaginal Dryness
        • Treatment for Vaginal Dryness
        • Product Market Overview for Vaginal Atrophy and Vaginal Dryness
        • 3.2.3.3 Dyspareunia
        • Epidemiology
        • Treatment Options for Dyspareunia
        • Dyspareunia Treatments in Development
        • Product Market Overview for Dyspareunia
  • Chapter 4. Themenopause Andmenopausal Symptoms
    • 4.1 Physiological Changes
    • 4.2 Epidemiology
    • 4.3 General Menopausal Symptoms
      • 4.3.1 Systemic Menopausal Symptoms
        • 4.3.1.1 Vasomotor Symptoms
        • Flushes/flashes
        • Sleep Disturbance
        • Headache
        • Palpitations
        • 4.3.1.2 Genitourinary Symptoms
        • Atrophic Vaginitis and Vulvar Atrophy
        • Atrophic Urethritis
        • 4.3.1.3 Other Systemic Conditions and Symptoms
        • Osteoporosis
        • Psychological Symptoms and Cognitive Deficits
        • Cardiovascular Symptoms
        • Breast Cancer
    • 4.4 Treatment for Menopause and Menopausal Symptoms
      • 4.4.1 Hormone Therapy
        • 4.4.1.1 Routes of Delivery for Hormonal Therapy
        • 4.4.1.2 Dosing Regimens for Hormone Therapy
      • 4.4.2 Other Pharmaceutical Therapies
    • 4.5 Products for Menopause and Menopausal Symptoms
      • 4.5.1 Hormone Replacement Therapy
        • 4.5.1.1 Oestrogen-Only Hormone Replacement Therapy
        • 4.5.1.2 Oestrogen and Progesterone Combined Hormone Replacement Therapy
        • 4.5.1.3 Testosterone, and Testosterone plus Oestrogen Combination Hormone
    • Replacement Therapy
      • 4.5.2 Products for Specific Menopausal Symptoms
    • 4.6 Product Market Overview for Hormone Replacement Therapies in Menopause
      • 4.6.1 Oestrogen-Only and Combined Hormonal Products
        • 4.6.1.1 Company
        • 4.6.1.2 Company
        • 4.6.1.3 Company
        • Sales Estimates and Product Market Outlook
        • 4.6.1.4 Company
        • Sales Estimates and Product Market Outlook
        • 4.6.1.5 Company
        • Sales Estimates and Product Market Outlook
        • 4.6.1.6 Company
        • Sales Estimates and Product Market Outlook
        • 4.6.1.7 Other Monotherapy and Combination Products by Delivery Route
    • 4.7 Product Market Overview for Hormonal Contraceptives in Menopause
    • 4.8 Hormone Therapy Market in Menopause
    • 4.9 Product Market Overview for Nonhormonal Products in Menopause
      • 4.9.1 Antidepressants for Vasomotor Symptoms
  • Chapter 5. Drugs Inresearch Anddevelopment For Obstetric And Gynaecological Conditions
    • 5.1 Drugs in Development for Infertility
      • 5.1.1 Drugs in Research and Development for Female Infertility
      • 5.1.2 Drugs in Development for Male-Factor Infertility
        • 5.1.2.1 AstraZeneca - Anastrozole
        • 5.1.2.3 Other
    • 5.2 Drugs in Development for Obstetric Conditions
      • 5.2.1 Preeclampsia
      • 5.2.2 Preterm Labour and Labour Induction
        • 5.2.2.6 Drugs in Development for Labour Induction
      • 5.2.3 Drugs in Development for Polycystic Ovary Syndrome
    • 5.3 Products in Development for Contraception
      • 5.3.1 Female Hormonal Oral Contraceptives
      • 5.3.3 Male Contraception
      • 5.3.4 Intrauterine Systems and Devices
        • 5.3.4.3 New Research Directions for Intrauterine Devices and Systems
    • 5.4 Products in Development for Menstrual and Gynaecological Disorders
      • 5.4.1 Menstrual Disorders and Syndromes
        • 5.4.1.7 Promising Research Direction in Menstrual Disorders
      • 5.4.2 Gynaecological Disorders
        • 5.4.2.1 Pain-Related Gynaecological Disorders
        • 5.4.2.2 Uterine Disorders
        • Other Promising Research Directions in Endometriosis
        • 5.4.2.3 Vaginal Disorders
    • 5.5 Products in Research and Development for Menopause
      • 5.5.1 Drugs in Clinical Development for Menopause and Vasomotor Symptoms
      • 5.5.2 Drugs in Clinical Development for Postmenopausal Osteoporosis
      • 5.5.3 Promising Research Directions in Postmenopausal Osteoporosis
  • Chapter 6. Theworld Gynaecology Market, 2007-2017
    • 6.1 Reproduction: Infertility and Obstetric Conditions
      • 6.1.1 The Global Market for Infertility and Obstetric Conditions, 2007-2017
        • 6.1.1.1 Market and Competitor Analysis: Infertility
        • Analysis of Gonadotrophins by Type
        • Market Outlook for Infertility
        • 6.1.1.2 Market Anal